KR870010029A - 1,5-벤조티아제핀유도체, 그의 제법 및 치료에의 응용 - Google Patents

1,5-벤조티아제핀유도체, 그의 제법 및 치료에의 응용 Download PDF

Info

Publication number
KR870010029A
KR870010029A KR870003554A KR870003554A KR870010029A KR 870010029 A KR870010029 A KR 870010029A KR 870003554 A KR870003554 A KR 870003554A KR 870003554 A KR870003554 A KR 870003554A KR 870010029 A KR870010029 A KR 870010029A
Authority
KR
South Korea
Prior art keywords
general formula
compound
compound according
group
represent
Prior art date
Application number
KR870003554A
Other languages
English (en)
Inventor
뮐러 쟝-클로드
뒤마 앙드레
Original Assignee
에뚜레 레메뜨르
신떼라보 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에뚜레 레메뜨르, 신떼라보 소시에떼 아노님 filed Critical 에뚜레 레메뜨르
Publication of KR870010029A publication Critical patent/KR870010029A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

1,5-벤조티아제핀유도체, 그의 제법 및 치료에의 응용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 다음 일반식(Ⅰ)에 해당하는 것을 특징으로 하는 순수한 광학 이성질체, 디아스테레오 이성체 또는 혼합물의 형태의 화합물 및 약리적으로 허용되는 산과의 그의 부가염.
    상기식에서,
    R은 수소 또는 선형 또는 분기형 C1-C4알킬기를 나타내고,
    R1및 R2는 따로 각각 선형 또는 분기형 C1-C4알킬기를 나타내거나 또는 다르게는
    R1과 R2는 함께 테트라메틸렌 또는 펜타메틸렌기를 나타낸다.
  2. 제1항에 있어서, 일반식(Ⅰ)에서 R, R1및 R2는 각각 메틸기를 나타내는 것을 특징으로 하는 화합물.
  3. 제1항에 있어서, (+)-시스-(2S,3S)-2-(4-메톡시페닐)-3-아세틸옥시-5-[(3R)-3-디메틸아미노-2-아세틸옥시프로필]-2,3-디히드로-5H-1,5-벤조티아제핀-4-온인것을 특징으로 하는 화합물.
  4. 일반식(Ⅱ)
    의 벤조티아제피논을 수소화나트륨으로 처리한 다음, 얻은 화합물을 일반식
    (여기서 Z는 크로로 또는 토실옥시기를 나타낸다)의 글리시딜 유도체와 반응시킨 다음 일반식 NHR1R2R1및 R2는 제1항에 정의한 바이다)의 아민과 반응시키고 최종적으로 일반식(Ⅲ)
    의 얻은 화합물을 일반식 RCOX(R은 제1항에 정의한 바이다)의 할로겐화아실에 의해 아실화시키는 것으로 이루어지는 것을 특징으로 하는 제1항에 따르는 화합물의 제조방법.
  5. 일반식(Ⅲ)
    (여기서 R1 과 R2는 제1항에 정의한 바이다)에 해당하는 것을 특징으로 하는 제4항에 따르는 제조방법에서 중간체로서 필요한 화합물.
  6. 제5항에 있어서, (+)-시스-(2S,3S)-2-(4-메톡시페닐)-3-히드록시-5-[(3R)-3-디메틸아미노-2-히드록시프로필]-2,3-디히드로-5H-1,5-벤조티아제핀-4-온 인것을 특징으로 하는 화합물.
  7. 제1항 내지 제3항중 어느 하나에 따르는 화합물로 구성되는 것을 특징으로 하는 의약 조성물.
  8. 제1항 내지 제3항중 어느 하나에 따르는 화합물을 적합한 부형제와 조합하여 포함하는 것을 특징으로 하는 의약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870003554A 1986-04-15 1987-04-14 1,5-벤조티아제핀유도체, 그의 제법 및 치료에의 응용 KR870010029A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR86-05346 1986-04-15
FR8605346A FR2597097B1 (fr) 1986-04-15 1986-04-15 Derives de benzothiazepine-1, 5, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
KR870010029A true KR870010029A (ko) 1987-11-30

Family

ID=9334233

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870003554A KR870010029A (ko) 1986-04-15 1987-04-14 1,5-벤조티아제핀유도체, 그의 제법 및 치료에의 응용

Country Status (18)

Country Link
US (1) US4743599A (ko)
EP (1) EP0242265B1 (ko)
JP (1) JPS62242674A (ko)
KR (1) KR870010029A (ko)
AT (1) ATE63908T1 (ko)
AU (1) AU586086B2 (ko)
CA (1) CA1283657C (ko)
DE (1) DE3770321D1 (ko)
DK (1) DK191587A (ko)
ES (1) ES2029845T3 (ko)
FI (1) FI871637A (ko)
FR (1) FR2597097B1 (ko)
GR (1) GR3002225T3 (ko)
HU (1) HU196776B (ko)
IL (1) IL82181A0 (ko)
NO (1) NO167286C (ko)
PT (1) PT84680B (ko)
ZA (1) ZA872683B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2703564B2 (ja) * 1987-07-31 1998-01-26 田辺製薬株式会社 １，５−ベンゾチアゼピン誘導体
FR2621584B1 (fr) * 1987-10-07 1991-05-24 Synthelabo Derives de benzothiazepine-1,5, leur preparation et leur application en therapeutique
FR2630109B1 (fr) * 1988-04-19 1991-11-29 Synthelabo Derives de ((n-(amino-2 oxo-2 ethyl)methylamino)-2 ethyl)-5 hydroxy-3 (methoxy-4 phenyl)-2 dihydro-2,3 5h-benzothiazepine-1,5 one-4, leur preparation et leur application en therapeutique
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
JP2863534B2 (ja) * 1988-10-24 1999-03-03 マリオン ラボラトリーズ，インコーポレイティド 医薬組成物
US4952692A (en) * 1989-04-04 1990-08-28 E. R. Squibb & Sons, Inc. Benzazepine derivatives
FR2669632B1 (fr) * 1990-11-22 1993-01-15 Synthelabo Derives de benzo-1, 5-thiazepine, leur preparation et leur application en therapeutique.
FR2672599B1 (fr) * 1991-02-08 1994-11-18 Synthelabo Derives de benzothiazepine-1,5, leur preparation et leur application en therapeutique.
US5580867A (en) * 1994-09-09 1996-12-03 Universite De Montreal Myocardial protection during ischemia and reperfusion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341519A (en) * 1965-04-28 1967-09-12 Squibb & Sons Inc Novel benzoxazines, benzothiazines, benzoxazepins and benzothiazepins
US3562257A (en) * 1967-10-28 1971-02-09 Tanabe Seiyaku Co Benzothiazepine derivatives

Also Published As

Publication number Publication date
EP0242265B1 (fr) 1991-05-29
PT84680B (pt) 1989-12-29
HU196776B (en) 1989-01-30
FI871637A0 (fi) 1987-04-14
US4743599A (en) 1988-05-10
AU7156487A (en) 1987-10-22
AU586086B2 (en) 1989-06-29
GR3002225T3 (en) 1992-12-30
NO167286C (no) 1991-10-23
PT84680A (fr) 1987-05-01
NO167286B (no) 1991-07-15
DK191587D0 (da) 1987-04-14
FR2597097B1 (fr) 1988-12-02
CA1283657C (en) 1991-04-30
ZA872683B (en) 1987-11-25
HUT45518A (en) 1988-07-28
DK191587A (da) 1987-10-16
ATE63908T1 (de) 1991-06-15
ES2029845T3 (es) 1992-10-01
EP0242265A1 (fr) 1987-10-21
FI871637A (fi) 1987-10-16
IL82181A0 (en) 1987-10-30
DE3770321D1 (de) 1991-07-04
NO871575L (no) 1987-10-16
NO871575D0 (no) 1987-04-14
JPS62242674A (ja) 1987-10-23
FR2597097A1 (fr) 1987-10-16

Similar Documents

Publication Publication Date Title
NO163566C (no) 1,5-benzothiazepinderivater som er anvendelige som utgangsmaterialer ved fremstilling av nye, terapeutisk aktive 8-klor-1,5-benzothiazepinderivater.
OA07151A (fr) Dérivés de la pyrrolidine .
KR870010029A (ko) 1,5-벤조티아제핀유도체, 그의 제법 및 치료에의 응용
ES2014482B3 (es) Nuevas 2-tiazolil imidazo/1,2-a/pirimidinas y sus sales, su procedimiento de preparacion, su aplicacion a titulo de medicamentos y las composiciones que las encierran.
SE8604950L (sv) Demensforbettrande och terapeutiska medel
GT198301599A (es) 4"-epi-eritromicina a y sus derivados como utiles agentes antibacterianos.
KR880009926A (ko) 알킬멜라토닌
KR890001969A (ko) 황화합물, 이들의 제법 및 이들을 함유하는 제약학적 조성물
ZA84261B (en) Bicyclo(4.2.0)1,3,5-octatriene derivatives,a process for their preparation and pharmaceutical compositions containing them
ES2037783T3 (es) Procedimiento para la obtencion de 3-aminosidnoniminas substituidas.
KR920002564A (ko) N-알킬 티아졸리딘 유도체
IT1204494B (it) Derivati della 1-stirene solfonil 2-osso 5-alcossi pirrolidina,loro procedimento di preparazione e loro applicazione come farmaci
SE8601798D0 (sv) Process for the preparation of eburnamenine derivatives
KR870008865A (ko) 나프토티아조시논
PT92175A (pt) Processo para a preparacao de 3-amino-sidnoniminas substituidas e de produtos intermediarios farmacologicamente activos
FI852465L (fi) Selektiva, biologiskt aktiva 7-oxo- prostacyklin-derivat samt framstaellningsfoerfarande foer dessa samt dessa innehaollande farmaceutiska kompositioner.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid